IBX — Imagion Biosystems Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- AU$2.42m
- AU$9.33m
- AU$1.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -916.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.43 | 0.5 | 0.24 | 0.57 | 1.65 | n/a | n/a | 34.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Imagion Biosystems Limited is a medical imaging company engaged in developing medical imaging technologies for various cancer types. The Company uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The Company operates through Research and Development segment. It is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Company’s lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
Directors
- Robert Proulx CHM
- Geoff Hollis CFO
- Dianne Angus NED
- Michael Harsh NED
- David Ludvigson NED
- Jovanka Naumoska NED
- Mark Van Asten NED
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 6th, 2016
- Public Since
- June 22nd, 2017
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 32,646,551
- Address
- Level 8, 55 Bourke Street, MELBOURNE, 3000
- Web
- https://imagionbiosystems.com/
- Phone
- Auditors
- RSM Australia Partners
Upcoming Events for IBX
Half Year 2024 Imagion Biosystems Ltd Earnings Release
Similar to IBX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Imagion Biosystems share price?
As of Today at 19:11 UTC, shares in Imagion Biosystems are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Imagion Biosystems share price performed this year?
Shares in Imagion Biosystems last closed at AU$0.07 and the price had moved by +362.5% over the past 365 days. In terms of relative price strength the Imagion Biosystems share price has outperformed the ASX All Ordinaries Index by +342.39% over the past year.
What are the analyst and broker recommendations for Imagion Biosystems?
There is no consensus recommendation for this security.
What is the Imagion Biosystems dividend yield?
Imagion Biosystems does not currently pay a dividend.
Does Imagion Biosystems pay a dividend?
Imagion Biosystems does not currently pay a dividend.
When does Imagion Biosystems next pay dividends?
Imagion Biosystems does not currently pay a dividend.
How do I buy Imagion Biosystems shares?
To buy shares in Imagion Biosystems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Imagion Biosystems?
As of the previous close price of AU$0.07, shares in Imagion Biosystems had a market capitalisation of AU$2.42m.
Where are Imagion Biosystems shares listed?
Here are the trading details for Imagion Biosystems:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IBX
What kind of share is Imagion Biosystems?
Based on an overall assessment of its quality, value and momentum Imagion Biosystems is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Imagion Biosystems share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Imagion Biosystems share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Imagion Biosystems. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +387.85%.
As of the last closing price of AU$0.07, shares in Imagion Biosystems were trading -30.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Imagion Biosystems PE Ratio?
The Imagion Biosystems PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Imagion Biosystems?
Imagion Biosystems' management team is headed by:
- Robert Proulx - CHM
- Geoff Hollis - CFO
- Dianne Angus - NED
- Michael Harsh - NED
- David Ludvigson - NED
- Jovanka Naumoska - NED
- Mark Van Asten - NED